Brief: Fate Therapeutics Announces Exercise By Ono Pharmaceutical Of Option To Her2-Targeted Car T-Cell Product Candidate For Solid Tumors

Fate Therapeutics

07/11/2022 14:03

Fate Therapeutics Inc  FATE.O :
    * FATE THERAPEUTICS ANNOUNCES EXERCISE BY ONO PHARMACEUTICAL
OF
OPTION TO HER2-TARGETED CAR T-CELL PRODUCT CANDIDATE FOR SOLID
TUMORS
    * FATE THERAPEUTICS - CO & ONO TO JOINTLY DEVELOP AND
COMMERCIALIZE FT825/ONO-8250 IN U.S. AND EUROPE WITH ONO HAVING
EXCLUSIVE RIGHTS IN REST OF WORLD
    * FATE THERAPEUTICS - UNDER TERMS OF AGREEMENT, CO TO GET
MILESTONE PAYMENT IN CONNECTION WITH ONO'S EXERCISE OF OPTION TO
FT825/ONO-8250
    * FATE THERAPEUTICS INC - FATE IS ELIGIBLE TO RECEIVE
CLINICAL,
REGULATORY AND COMMERCIAL MILESTONE PAYMENTS
    * FATE THERAPEUTICS - FATE IS ELIGIBLE TO RECEIVE TIERED
ROYALTIES
ON NET SALES OUTSIDE OF UNITED STATES AND EUROPE BY ONO

Source text for Eikon:  ID:nGNX5Z6jfG 
Further company coverage:  FATE.O